Obesity treatment paradigms should target those at risk for diabetes.


Lifestyle modifications, weight-loss medications and bariatric surgery are the three major modalities that will have clinical implications on the prevention and treatment of obesity, according to data presented here.

“With effective options in all of these three treatment modalities, we can now evolve rational data-driven models of care that treat obesity as a medical illness,” W. TimothyGarvey, MD, professor and chair in the department of nutrition sciences at the University of Alabama at Birmingham, and senior scientist at the Nutrition Obesity Research Center, told Endocrine Today.

W. Timothy Garvey

Emerging therapies

During a presentation on emerging obesity therapies, Garvey reported recent data on phentermine-topiramate (Qsymia, Vivus) and lorcaserin (Belviq, Eisai), both of which gained approval in adults with an initial BMI of at least 30 or in those with a BMI of at least 27 and at least one weight-related condition, such as hypertension, type 2 diabetes or dyslipidemia.

“We’re in an exciting phase of drug development for obesity, with two drugs approved in the summer of 2012 that appear to be safe and effective for the treatment of obesity,” Garvey said.

“In addition, we have two other drugs that have finished or will soon finish phase 3 trials.”

One of these is bupropion/naltrexone (Contrave, Orexigen), an experimental agent now finished with phase 3 clinical trials. According to Garvey, a cardiovascular outcomes study is currently ongoing as requested by the FDA before approval. “The BP did not increase with the drug, but it didn’t go down to the extent that you’d predict with the weight loss achieved,” he said. “This will be the first cardiovascular outcomes study with a weight-loss drug where the data will be available in, perhaps, 2014.”

About an 8% weight loss was demonstrated and sustained during 1 year compared with 2% with placebo, Garvey said.

Furthermore, he referenced recent data from a 56-week, double blind, phase 3a clinical trial investigating higher-dose liraglutide (Victoza, Novo Nordisk) as a potential treatment for maintained weight loss in overweight or obese patients with type 2 diabetes. The manufacturer recently released the second phase 3a trial results from the clinical development program for liraglutide 3 mg as an obesity treatment.

“About 4 kg were lost on lifestyle intervention alone, and up to 9 kg were lost with high-dose liraglutide. There are 2-year data indicating that its efficacy for sustaining this weight loss is evident,” Garvey said.

Bariatric surgery

However, Garvey said medical and surgical interventions provide the best outcomes in obese patients with complications, and optimal benefit–risk occurs when weight loss is used as a tool to treat these complications of obesity.

As an adjunct to lifestyle modification, the aforementioned new medical therapies can result in a 10% loss of body weight, but if a patient begins with a BMI of 38, he will likely be obese when therapies are complete, Garvey said.

“However, that 10% loss of body weight is sufficient to improve insulin sensitivity, glucose homeostasis, lipid levels, BP, diabetes prevention, CVD risk factors and better control of both glucose and BP in patients with type 2 diabetes. We’re achieving an amount of weight loss here that’s in fact beneficial in terms of cardiometabolic disease,” he said.

Moving forward

Garvey concluded with the economic burden of diabetes and obesity on the United States health care system. He told Endocrine Today that for the clinical research community to address the diabetes and obesity epidemics, the progression from prediabetes to diabetes should first be considered.

“A rational and effective obesity treatment paradigm that targets resources to patients who are at highest risk will be cost-effective in preventing diabetes,” he said. “The numbers vary, but it costs much more per year to take care of a patient with diabetes than it does to take care of a patient without diabetes.”

Source: Endocrine today

 

The science of obesity: what do we really know about what makes us fat? An essay by Gary Taubes .


The history of obesity research is a history of two competing hypotheses. Gary Taubesargues that the wrong hypothesis won out and that it is this hypothesis, along with substandard science, that has exacerbated the obesity crisis and the related chronic diseases. If we are to make any progress, he says, we have to look again at what really makes us fat

Since the 1950s, the conventional wisdom on obesity has been simple: it is fundamentally caused by or results from a net positive energy balance—another way of saying that we get fat because we overeat. We consume more energy than we expend. The conventional wisdom has also held, however, that efforts to cure the problem by inducing undereating or a negative energy balance—either by counselling patients to eat less or exercise more—are remarkably ineffective.

Put these two notions together and the result should be a palpable sense of cognitive dissonance. Take, for instance, The Handbook of Obesity, published in 1998 and edited by three of the most influential authorities in the field. “Dietary therapy,” it says, “remains the cornerstone of treatment and the reduction of energy intake continues to be the basis of successful weight reduction programs.” And yet it simultaneously describes the results of such dietary therapy as “poor and not long-lasting.”1

Rather than resolve this dissonance by questioning our beliefs about the cause of obesity, the tendency is to blame the public (and obese patients implicitly) for not faithfully following our advice. And we embrace the relatively new assumption that obesity must be a multifactorial and complex disorder. This makes our failures to either treat the disorder or rein in the burgeoning epidemics of obesity worldwide somehow understandable, acceptable.

Another possibility, though, is that our fundamental understanding of the aetiology of the disorder is indeed incorrect, and this is the reason for the lack of progress. If this is true, and it certainly could be, then rectifying this aetiological misconception is absolutely critical to future progress.

Energy balance hypothesis

Despite its treatment as a gospel truth, as preordained by physical law, the energy balance or overeating hypothesis of obesity is only that, a hypothesis. It’s largely the product of the influential thinking of two physicians—the German diabetes specialist Carl von Noorden at the beginning of the 20th century, and the American internist and clinical investigator Louis Newburgh, a quarter century later. Its acceptance as dogma came about largely because its competing hypothesis—that obesity is a hormonal, regulatory disorder—was a German and Austrian hypothesis that was lost with the anti-German sentiment after the second world war and the subsequent embracing of English, rather than German, as the lingua franca of science.

Medicine today is often taught untethered from its history—unlike physics, for instance—which explains why the provenance of the energy balance hypothesis is little known, even by those physicians and researchers who are its diehard proponents. Nor is it widely known that a competing hypothesis ever existed, and that this hypothesis may have done a better job of explaining the data and the observations. Knowing this history is crucial to understanding how we got into the current situation and, indeed, how we might solve it.

The applicability of the laws of thermodynamics to living organisms dates from the 1880s and the research of the German physiologist Max Rubner. By the end of the 19th century, the American scientists Wilbur Atwater and Francis Benedict had confirmed that these laws held for humans as well: that the calories we consumed would be burned as fuel, stored, or excreted.2 This revelation then led von Noorden to propose that “the ingestion of a quantity of food greater than that required by the body, leads to an accumulation of fat, and to obesity, should the disproportion be continued over a considerable period.”3

By the late 1920s, Newburgh had taken up the energy balance banner at the University of Michigan and was promoting it based on what he believed to be a fundamental truth: “All obese persons are alike in one fundamental respect—they literally overeat.” As such, he blamed obesity on either a “perverted appetite” (excessive energy consumption) or a “lessened outflow of energy” (insufficient expenditure).4 If the obese person’s metabolism was normal, he argued, and they still refused to rein in their intake, that was sufficient evidence to assume that they were guilty of “various human weaknesses such as overindulgence and ignorance.”5

By 1939, Newburgh’s biography at the University of Michigan was crediting him with the discovery that “the whole problem of weight lies in regulation of the inflow and outflow of calories” and for having “undermined conclusively the generally held theory that obesity is the result of some fundamental fault.”6

As sceptics pointed out at the time, though, the energy balance notion has an obvious flaw: it is tautological. If we get fatter (more massive), we have to take in more calories than we expend—that’s what the laws of thermodynamics dictate—and so we must be overeating during this fattening process. But this tells us nothing about cause. Here’s the circular logic:

Why do we get fat? Because we overeat.

How do we know we’re overeating? Because we’re getting fatter.

And why are we getting fatter? Because we’re overeating.

And so it goes, round and round.

“The statement that primary increase of appetite may be a cause of obesity does not lead us very far,” wrote the Northwestern University School of Medicine endocrinologist Hugo Rony in 1940 in Obesity and Leanness, “unless it is supplemented with some information concerning the origin of the primarily increased appetite. What is wrong with the mechanism that normally adjusts appetite to caloric output? What part of this mechanism is primarily disturbed?” Any regulatory defect that drove people to gain weight, Rony noted, would induce them to take in more calories than they expend. “Positive caloric balance would be, then, a result rather than a cause of the condition.”7

Endocrinological hypothesis

The alternative hypothesis that Newburgh’s work had allegedly undermined was the idea that some “intrinsic abnormality”—Rony’s words—was at the root of the disorder. This was an endocrinological hypothesis. It took the laws of physics as a given; it rejected aberrant behaviour or ignorance as causal. It existed at the time as two distinct hypotheses.

One was the brainchild of Wilhelm Falta, a student of von Noorden and a pioneer of the science of endocrinology. Falta believed that the hormone insulin must be driving obesity on the basis, as he noted as early as 1923, that “a functionally intact pancreas is necessary for fattening.”8 Once insulin was discovered, Falta considered it the prime suspect in obesity. “We can conceive,” he wrote, “that the origin of obesity may receive an impetus through a primarily strengthened function of the insular apparatus, in that the assimilation of larger amounts of food goes on abnormally easily, and hence there does not occur the setting free of the reactions that in normal individuals work against an ingestion of food which for a long time supersedes the need.”9

The other version of the hypothesis was bound up in a concept known as lipophilia. It was initially proposed in 1908 by Gustav Von Bergmann, a German authority on internal medicine, and then taken up by Julius Bauer, who did pioneering work on endocrinology, genetics, and chronic disease at the University of Vienna.

Von Bergmann initially evoked the term lipophilia (“love of fat”) to explain why fat deposition was not uniform throughout the body. Just as we grow hair in some places and not others, according to this thinking, we fatten in some areas and not others and biological factors must regulate this. People who are constitutionally predisposed to fatten, Von Bergmann proposed, had adipose tissue that was more lipophilic than that of constitutionally lean individuals. And if fat cells were accumulating excessive calories as fat, this would deprive other organs and cells of the energy they needed to thrive, leading to hunger or lethargy. These would be compensatory effects of the fattening process, not causes.

“Like a malignant tumor or like the fetus, the uterus or the breasts of a pregnant woman,” explained Bauer, “the abnormal lipophilic tissue seizes on foodstuffs, even in the case of undernutrition. It maintains its stock, and may increase it independent of the requirements of the organism. A sort of anarchy exists; the adipose tissue lives for itself and does not fit into the precisely regulated management of the whole organism.”10

Erich Grafe, director of the Clinic of Medicine and Neurology at the University of Würtzberg, discussed these competing hypotheses in his seminal textbook Metabolic Diseases and Their Treatment, which was published in an English translation in 1933. Grafe said he favoured the energy balance model of obesity, but acknowledged that this model failed to explain key observations—why fat accumulates in certain regions of the body. “The energy conception certainly cannot be applied to this realm,” Grafe wrote. The lipophilia hypothesis could.

Grafe described lipophilia as “a condition of abnormally facilitated fat production and impeded fat destruction . . . a sort of lipomatosis universalis, in the sense that the lipophilia in certain tissues is primary and the sparing in the energy expended is secondary.” But he found the hypothesis troubling “so far as it presupposes overnutrition.” He acknowledged, nonetheless, that it was “a good working hypothesis.” As for Falta’s notions, Grafe wrote, “the fact that insulin is an excellent fattening substance has been observed.”11

By 1938, Russell Wilder of the Mayo Clinic (later to become director of the National Institute of Arthritis and Metabolic Diseases) was writing that the lipophilia hypothesis “deserves attentive consideration,” and that “the effect after meals of withdrawing from the circulation even a little more fat than usual might well account both for the delayed sense of satiety and for the frequently abnormal taste for carbohydrate encountered in obese persons . . . A slight tendency in this direction would have a profound effect in the course of time.”12

Two years later, Rony wrote in Obesity and Leanness that the hypothesis was “more or less fully accepted” in Europe.

Language barrier

Maybe so. But it was lost with the second world war and the embracing of English as the lingua franca of science afterwards. In Grafe’s chapters on obesity, over 90% of the 235 references are from the German language literature. In Rony’s Obesity and Leanness, this is true for a third of the almost 600 references. But post-war, the German language references fall away quickly. In Obesity…, published in 1949 by two Mayo Clinic physicians—Edward Rynearson and Clifford Gastineau—only 14 of its 422 references are from the German language literature, compared with a dozen from Louis Newburgh alone. By the late 1960s and 1970s, when the next generation of textbooks were written, German language references were absent almost entirely, as were the clinical observations, experience, and intuitions that went with them.

By then, obesity had evolved into an eating disorder, to be treated and studied by psychologists and psychiatrists, while laboratory researchers focused (as they still do) on identifying the physiological determinants of hunger, satiety, and appetite: why do we eat too much, rather than why do we store too much fat? Two entirely different questions.

What makes this transition so jarring in retrospect is that it coincided with the identification of the hormone insulin in the early 1960s as the primary regulator of fat accumulation in fat cells.13 Had Falta’s ideas and the lipophilia hypothesis survived the second world war, this discovery would have served to bring these two hypotheses together. And because serum insulin levels are effectively driven by the carbohydrate content of the diet, this hypothesis would implicate refined, high glycaemic grains and sugars (sucrose and high fructose corn syrup, in particular) as the environmental triggers of obesity. They would be considered uniquely fattening, just as Falta had suggested, not because we overeat them—whatever that means—but because they trigger a hormonal response that drives the partitioning of the fuel consumed into storage as fat.

This might have been perceived, although it was not, as a medical triumph: the elucidation of both the biological underpinnings of obesity as well as an explanation for what was until then the conventional wisdom on the cause. “Every woman knows that carbohydrate is fattening,” as Reginald Passmore and Yola Swindells wrote in the British Journal of Nutrition in 1963: “this is a piece of common knowledge, which few nutritionists would dispute.”14

Academic backlash

That this insulin-carbohydrate hypothesis never gained traction can be explained, paradoxically, by the fact that it was embraced by practising physicians, who read the physiology and biochemistry literature and then designed carbohydrate restricted diet plans that seemed to work remarkably well. Indeed, the sessions on dietary therapy for obesity in the scattering of obesity conferences held from the end of the second world war through the mid-1970s invariably focused on the surprising efficacy of carbohydrate restricted diets to reduce excess adiposity.

When those physicians then wrote diet books based on their regimens, and these books then sold exceedingly well—Dr Atkins’ Diet Revolution (1972) most notably—the result was a backlash from academic nutritionists and obesity researchers. Fred Stare, for instance, head of the Harvard nutrition department, testified in 1972 Congressional hearings that physicians prescribing such diets were “guilty of malpractice,” on the basis that these diets were rich in saturated fat at a time when the medical community was coming to believe that high fat diets were the cause of heart disease. Exacerbating the dietary fat issue was the fact that these diet plans encouraged obese individuals to eat to satiety, effectively as much as they wanted (so long as they avoided carbohydrates), when the conventional wisdom had it that they got fat to begin with precisely because they ate as much as they wanted.

By the mid-1970s, the diets had been successfully tarred as dangerous fads (despite a history of common use in hospitals, including the Harvard Medical School,15 and a provenance going back at least to the 1820s) and the physician authors as quacks and confidence men. The notion that obesity is not an eating disorder or an energy balance disorder, but a fat accumulation disorder—a hormonal, regulatory disorder—triggered not by energy imbalance but the quality and quantity of the carbohydrates in the diet, has been routinely dismissed ever since as unworthy of serious attention.

In a 21st century of genomics, proteomics, and high tech medicine, it’s hard to imagine that the obesity problem might have been effectively solved by 1960s era endocrinology. Rather we assume that these competing hypotheses must have been rigorously tested, and the energy balance hypothesis must have won out. We know that it’s excess calories, not carbohydrates—eating too much rather than “abnormal lipophilic tissue”—that make us fat because that’s what the science has told us.

But this is not the case. One problem has been an almost ubiquitous misunderstanding of the alternative hypothesis and, indeed, of energy imbalance itself. The existence of an energy imbalance in people who are getting fatter is treated, as Newburgh did, as evidence that the energy balance hypothesis is correct. The same can be said for observations that obese people eat more than lean or are more sedentary, or even that per capita food availability has increased over the course of the obesity epidemic or that leisure time physical activity has decreased. All these observations, though, are consistent with both hypotheses.

Calories or carbohydrates

Attempts to blame the obesity epidemics worldwide on increased availability of calories typically ignore the fact that these increases are largely carbohydrates and those carbohydrates are largely sugars—sucrose or high fructose corn syrup. And so these observations shed no light on whether it’s total calories to blame or the carbohydrate calories. Nor do they shed light on the more fundamental question of whether people or populations get fat because they’re eating more, or eat more because the macronutrient composition of their diets is promoting fat accumulation—increased lipogenesis or decreased lipolysis, in effect, driving an increase in appetite.

The same is true for bariatric surgery, which is now acknowledged to be a remarkably effective means of inducing long term weight loss. But does weight loss occur after surgery because of the rearrangement of the gastrointestinal tract resulting in hormonal effects that minimise appetite or directly minimise fat accumulation? Does it occur because the patient reduces total calories consumed after surgery or reduces carbohydrate calories and, specifically, refined grains and sugars? The observation that bariatric surgery works doesn’t answer these questions.

As Erich Grafe noted about the lipophilia hypothesis 80 years ago, it “presupposes overnutrition.” If a patient is getting heavier, they must be taking in more energy than they expend. With the energy balance hypothesis, overnutrition is causal; with lipophilia, it’s compensatory, a response to the hormonally driven fat accumulation. Either way, it has to exist while an individual is gaining weight. And, by the same token, undernutrition or negative energy balance has to exist if an individual is losing weight.

Sugary beverages are another example of how these different hypotheses lead to different conclusions that are relevant to solving the obesity epidemics worldwide. The conventional wisdom has it that sugary beverages are merely empty calories that we consume in excess, although it is possible that the metabolism of fructose (a key carbohydrate component that makes these sugars sweet) in the liver somehow circumvents leptin signalling, leading us to consume these beverages and their calories even when we’re not and shouldn’t be hungry. The hormonal or regulatory hypothesis also focuses on the metabolism of fructose in the liver, but rather than leptin it uses evidence suggesting that fructose metabolism can induce insulin resistance, leading in turn to raised insulin levels and trapping fat in fat cells—increasing, in effect, lipophilia.

Shortcomings of obesity and nutrition research

Another problem endemic to obesity and nutrition research since the second world war has been the assumption that poorly controlled experiments and observational studies are sufficient basis on which to form beliefs and promulgate public health guidelines. This is rationalised by the fact that it’s exceedingly difficult (and inordinately expensive) to do better science when dealing with humans and long term chronic diseases. This may be true, but it doesn’t negate the fact the evidence generated from this research is inherently incapable of establishing reliable knowledge.

The shortcomings of observational studies are obvious and should not be controversial. These studies, regardless of their size or number, only indicate associations—providing hypothesis generating data—not causal relations. These hypotheses then have to be rigorously tested. This is the core of the scientific process. Without rigorous experimental tests, we know nothing meaningful about the cause of the disease states we’re studying or about the therapies that might work to ameliorate them. All we have are speculations.

As for the experimental trials, these too have been flawed. Most conspicuous is the failure to control variables, particularly in free-living trials. Researchers counsel participants to eat diets of different macronutrient composition—a low fat, a low carbohydrate, and a Mediterranean diet, for instance—and then send them off about their lives to do so. In these trials, carbohydrate restricted diets almost invariably show significantly better short term weight loss, despite allowing participants to eat as much as they want and being compared with calorie restricted diets that also reduce the quantity of carbohydrates consumed and improve the quality. In these trials, the ad libitum carbohydrate restricted diets have also improved heart disease and diabetes risk factors better than the diets to which they’ve been compared. But after a year or two, the results converge towards non-significance, while attempts to quantify what participants actually eat consistently conclude that there is little long term compliance with any of the diets.1617 18

Rather than acknowledge that these trials are incapable of answering the question of what causes obesity (assumed to be obvious, in any case), this research is still treated as relevant, at least, to the question of what diet works best to resolve it—and that in turn as relevant to the causality question. Should we restrict calories or carbohydrates to lose weight? If the answer is that it doesn’t seem to matter because the participants eventually fail to adhere to any of the diets, this is perceived as somehow a confirmation that the only way to lose weight is to reduce calories, and so the energy balance hypothesis is the correct one.19

Imagine drawing conclusions about the cause of lung cancer or the reduction in risk that can be achieved by quitting cigarettes based on success rates in experimental trials of smoking cessation techniques—going cold turkey, for instance, versus using the patch or nicotine gum. The logic is similar if not identical.

Ultimately what we want to know is what causes weight gain. That’s an entirely different question from whether advising someone to follow a Mediterranean diet is more or less efficacious than a low fat or a carbohydrate restricted diet or some variation thereof.

In metabolic ward studies, in which the diets of the participants have been well controlled, researchers typically restricted the calories in both arms of the trials—feeding participants, say, 800 calories of a low fat versus a low carbohydrate diet—and so building into the study design one of the hypotheses that is ultimately being tested. What we want to know, again, is what causes us to gain weight, not whether weight loss can be induced under different conditions of both semistarvation and carbohydrate restriction.

What can we do about this? It seems we have two choices. We can continue to examine and debate the past, or we can look forward and start anew.

A year ago, working with Peter Attia, a physician, and with support from the Laura and John Arnold Foundation in Houston Texas, I cofounded a not-for-profit organisation called the Nutrition Science Initiative (NuSI.org). Our strategy is to fund and facilitate rigorously well controlled experimental trials, carried out by independent, sceptical researchers. The Arnold Foundation has now committed $40m over the next three years to this research programme. Our hope is that these experiments will be the first steps in answering definitively the question of what causes obesity and help us finally make meaningful progress against it.

We believe that ultimately three conditions are necessary to make progress in the struggle against obesity and its related chronic diseases—type 2 diabetes, most notably. First is the acceptance of the existence of an alternative hypothesis of obesity, or even multiple alternative hypotheses, with the understanding that these, too, adhere to the laws of physics and must be tested rigorously.

Second is a refusal to accept substandard science as sufficient to establish reliable knowledge, let alone for public health guidelines. When the results of studies are published, the authors must be brutally honest about the possible shortcomings and all reasonable alternative explanations for what they observed. “If science is to progress,” as the Nobel prize winning physicist Richard Feynman said half a century ago, “what we need is the ability to experiment, honesty in reporting results—the results must be reported without somebody saying what they would like the results to have been—and finally—an important thing—the intelligence to interpret the results. An important point about this intelligence is that it should not be sure ahead of time what must be.”20

Finally, if the best we’ve done so far isn’t good enough—if uncontrolled experiments and observational studies are unreliable, which should be undeniable—then we have to find the willingness and the resources to do better. With the burden of obesity now estimated at greater than $150bn (£100bn; €118bn) a year in the US alone, virtually any amount of money spent on getting nutrition research right can be defended on the basis that the long term savings to the healthcare system and to the health of individuals will offset the costs of the research by orders of magnitude.

Source: BMJ

‘Weight is healthy’ study criticised.


_65040849_hi004255563

 

What is a healthy weight?

 

A study which suggests being overweight can lead to a longer life has caused controversy among obesity experts.

One labelled the findings a “pile of rubbish” while another said it was a “horrific message” to put out.

The research, in the Journal of the American Medical Association, suggested the overweight were less likely to die prematurely than people with a “healthy” weight.

Being underweight or severely obese did cut life expectancy.

The researchers at the US National Centre for Health Statistics looked at 97 studies involving nearly 2.9 million people to compare death rates with Body Mass Index (BMI) – a way of measuring obesity using a person’s weight and height.

A healthy BMI is considered to be above 18.5 and below 25. However, overweight people (with a BMI between 25 and 30) were 6% less likely to die early than those considered to have a healthy weight, the study reports.

Have you ever seen a 100-year-old human being who is overweight? The answer is you probably haven’t.”

Prof John Wass Royal College of Physicians

Mildly obese people (BMI between 30 and 35) were no more likely to die prematurely than people with a healthy BMI.

The study said being “overweight was associated with significantly lower all-cause mortality”.

Possible explanations included overweight people getting medical treatment, such as to control blood pressure, more quickly or the extra weight helping people survive being severely ill in hospital.

However, the researchers point out they looked only at deaths and not years spent free of ill-health.

Unconvinced

On Tuesday, the Royal College of Physicians called for the UK to rethink the way it tackles obesity.

Prof John Wass, vice-president of the college, said: “Have you ever seen a 100-year-old human being who is overweight? The answer is you probably haven’t.”

He said the largest people will have died years before and pointed to health problems and higher levels of Type 2 diabetes.

“Huge pieces of evidence go against this, countless other studies point in the other direction.”

Other experts criticised the research methods.

“Some portion of those thin people are actually sick, and sick people tend to die sooner,” according to Donald Berry, from the University of Texas

Dr Walter Willett, from the Harvard School of Public Health said: “This is an even greater pile of rubbish” than a study conducted by the same group in 2005.

Tam Fry, from the National Obesity Forum in the UK, said: “It’s a horrific message to put out at this particular time.

“We shouldn’t take it for granted that we can cancel the gym, that we can eat ourselves to death with black forest gateaux.”

Source:BBC

Obesity increases surgery time, cost in patients with lung cancer.


In a recent study published in The Annals of Thoracic Surgery, researchers determined that for every 10-unit increase in BMI, operating room time increased by 7.2 minutes for lung cancer patients undergoing lobectomy. While this increase may not seem substantial, researchers suggest the cost burden is more worrisome.

“The fact that we are putting more and more costly resources into caring for obese patients needs to be considered as hospitals and policy makers think of ways to control future health care costs. More public health emphasis on healthy lifestyle choices and weight loss is needed,” researcher Jamii B. St. Julien, MD, MPH, from Vanderbilt University Medical Center in Nashville, said in a press release.

St. Julien and colleagues included lung cancer patients in The Society of Thoracic Surgeons General Thoracic Surgery database (STS GTSD) who also underwent lobectomy as a primary procedure between 2006-2010 (n=19,337) for the multi-institutional, retrospective study.

Mean BMI measurements were 27.3 kg/m2 for 13,222 patients (68.4%) with a BMI <30 kg/m2; 4,898 patients (25.3%) had a BMI of 30 kg/m2 or more; and 625 patients were morbidly obese. There was no BMI data for 1,217 patients (6.3%), researchers wrote.

Prior to multivariate regression analysis, the average total operating room time was 240.1 minutes; preprocedure time was 48.4 minutes, procedure time was 174.1 minutes and postprocedure time was 17.4 minutes. The researchers said that length of stay tended to be 6.9 days, with an average 1.8% overall 30-day mortality rate.

Upon further analysis, the researchers wrote that for every 10-unit increase in BMI, there was a 7.2-minute increase in operating room time (P<.0001).

“For example, a lobectomy in a patient with a BMI of 45 kg/m2 takes approximately 15 minutes longer than for a patient with a BMI of 25 kg/m2,” researchers wrote.

This increase in operating room time led to cost estimates within the study. Every 10-unit increase in BMI has the potential to cost an additional $446, the researchers wrote. However, it remains difficult to estimate the true cost, they added.

“As any clinician will attest, an additional 7 minutes of total operating room time for an obese patient hardly seems clinically significant. However, I do not believe the authors consider this clinically relevant either,” David R. Jones, MD, from the department of surgery in the division of thoracic and cardiovascular surgery at the University of Virginia, wrote in an invited commentary accompanying the study. “Instead, I think the intent of this publication is to begin the process of deducing the true cost of performing thoracic procedures in the ever-increasing obese population.”

Jones wrote that he agrees more obese patients will require thoracic surgical procedures, and that a better understanding of both the obesity and lung cancer epidemic is valuable.

Disclosure: Grogan is a recipient of the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service career Development Award. St. Julien is a recipient of the Vanderbilt University Surgical Oncology T32 Training Grant. All other researchers report no relevant financial disclosures.

Perspective

 

George A. Bray

  • Obesity is a common problem and carries with it the risk for many kinds of other ailments. It can also be a handicap when it comes to surgical and other medical procedures. This is clearly illustrated in this paper on surgical treatment. Obesity can also pose challenges for anesthesia during surgery, for post-operative recovery and for wound healing in the post-operative state.
    • George A. Bray, MD
    • Endocrine Today Editorial Board member

 

  • Source: Endocrine Today.

 

Early menarche may predict overall obesity.


Cardiovascular disease is the leading cause of death in women in the United States, but little is known about the effect of reproductive factors. In a recent substudy of the Framingham Heart Study, researchers determined that earlier age of menarche is linked to overall obesity.

“The purpose of this study was to examine whether female reproductive risk factors — including onset of menarche, number of births over a lifetime (parity), onset of menopause and menopausal status — are all associated with indices of body fat composition,” researcher Caroline S. Fox, MD, MPH, of the National Heart, Lung, and Blood Institute, said in a press release.

Researchers analyzed 1,638 patients (aged 40 years or older; weighing less than 160 kg) from the multidetector CT (MDCT) substudy of the Framingham Heart Study (FHS) from 2002 to 2005. The patients were offspring of the FHS and third-generation cohorts.

Besides female reproductive risk factors measured, the researchers also looked at visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) via MDCT.

To better understand the influences of body fat and female reproductive risk factors, the researchers also adjusted for covariates such as age, smoking status, alcohol consumption, physical activity, hormone therapy use and menopausal status.

According to data, earlier age of menarche was associated with increased BMI, waist circumference, VAT and SAT (all P<.0001). The researchers wrote that for each 1-year increase in menarche age, VAT was 61 cm3 lower. However, this association of earlier menarche with adiposity measures was weakened after adjustments for BMI. Associations between adiposity and parity, besides menopausal age, were not statistically significant, they added.

Although postmenopausal women had increased BMI, waist circumference, VAT and SAT compared with premenopausal women, the researchers said this was due to increased ages among postmenopausal women.

“This research suggests that select female reproductive risk factors, specifically onset of menarche, are associated with overall adiposity, but not with specific indices of body fat distribution,” researcher Subbulaxmi Trikudanathan, MD, of Harvard Medical School, said in a press release. “Ultimately, the important question is whether female reproductive risk factors can be used to target lifestyle interventions in high-risk women to prevent the metabolic consequences of obesity and cardiovascular disease.”

The researchers suggest that further studies determine whether female reproductive factors can be used in lifestyle interventions among women at high risk for the metabolic consequences of obesity and CVD.

  • Source: Endocrine Today

 

Obesity Epidemic Not Due to High Fructose Corn Syrup?


A staggering two-thirds of Americans are overweight, and about one-quarter to one-third of adults fall into the obese category and it is projected to go to FIFTY percent by 2030.

Obesity is now so common that it leads to more doctor visits than smoking1 – and rates have been on the rise for decades now.

The fact that obesity is now an epidemic is not up for debate. What’s causing it, however, is.

One of the forerunning theories is that dramatic changes in our dietary patterns such as the extensive use of sugar, primarily in the form of high fructose corn syrup (HFCS), which is added to virtually all processed foods, is prompting metabolic dysfunction that is making people gain weight.

Now a new study has come out claiming it has “proof” that HFCS is not to blame… but wouldn’t you know it, the study’s authors were funded by, or have links to, the corn industry.

No Link Between High Fructose Corn Syrup and Obesity?

The new report, published in the International Journal of Obesity, says there is no evidence to suggest that the U.S. obesity epidemic can be blamed on HFCS consumption.2 The authors reviewed existing HFCS research and concluded that there are no short-term health differences (such as weight gain, appetite, insulin or glucose levels) between the use of HFCS and sugar (sucrose), noting that both are similar in composition and absorbed identically in the GI tract.

This is the most common argument used by the corn industry to support their agenda that HFCS is safe. Sucrose (table sugar) is 50 percent glucose and 50 percent fructose. High fructose corn syrup (HFCS) is anywhere from 42 to 55 percent fructose depending on which type is used.

While it’s true that they are similar in composition – their parts are metabolized very differently in your body. Because high-fructose corn syrup contains free-form monosaccharides of fructose and glucose, it cannot be considered biologically equivalent to sucrose, which has a glycosidic bond that links the fructose and glucose together, and which slows its break down in the body.

Even if this obvious metabolic difference were not present, it is important to point out that glucose is the form of energy your body is designed to run on. Every cell in your body uses glucose for energy, and it’s metabolized in every organ of your body; about 20 percent of glucose is metabolized in your liver. Fructose, on the other hand, can only be metabolized by your liver, because your liver is the only organ that has the transporter for it.

Fructose is the Real Culprit

Since all fructose gets shuttled to your liver, and, if you eat a typical Western-style diet, you consume high amounts of it, fructose ends up taxing and damaging your liver in the same way alcohol and other toxins do. And just like alcohol, fructose is metabolized directly into fat – not cellular energy, like glucose.

While in times of complete glycogen depletion (i.e. post work-out or true hunger), fructose can be used to replenish these stores, any excess will mostly be converted to fat. So, eating fructose in excess of the very small amount our body can handle is really like eating fat – it just gets stored in your fat cells, which leads to mitochondrial malfunction, obesity and obesity-related diseases.

So both sugar and HFCS play a role in the obesity epidemic, but it’s important to understand that the claim you hear on TV, that “sugar is sugar” no matter what form it’s in, is a misstatement that can, quite literally, kill you – albeit slowly.

The more fructose a food contains, and the more total fructose you consume, the worse it is for your health.

It’s important to note that both sugar and HFCS are problematic, as they both contain similar amounts of fructose, the true culprit. But the reason why HFCS may, in fact, be even worse than table sugar, despite having similar fructose content, is both due to the aforementioned difference in metabolizing it (sucrose’s glycosidic bond) and due to its liquid form. When you consume fructose in liquid form, such as drinking a soda, it places an even more intense burden on your liver. The effect on your liver is not only sped up but also magnified.

Cost Is King

Even if one were to ignore the evidence reviewed above and accept the corn industry’s argument that there is no significant biochemical difference between the fructose in HFCS and regular table sugar, one can’t escape the quantity argument. There is simply no defense against it. In the mid ’70s, Japanese scientists discovered how to manufacture HFCS cheaply from corn. Because it is so cheap it is used in massive quantities.

Fructose in small quantities is relatively harmless. Our ancestors would typically consume some on a regular basis, typically in the form of fruits, but they would rarely consume it in quantities greater than 15 grams (one tablespoon) a day. Now the average intake is FIVE times that at 75 grams and some people consume more than 10 times that amount. At those levels fructose becomes a pernicious liver and metabolic toxin.

Another Case of Industry-Funded Propaganda?

But here is where it gets really interesting. There are actually clever forces at work behind the scenes that have carefully orchestrated this information to deceive you and the rest of the public. So why does this new study make it sound like HFCS has been nothing more than an unfortunate scapegoat in this whole scenario?

As I have explained in a previous video, it is usually helpful to examine who authored the study, and where their funding and true loyalties lie. And in this case, doing so proved to be very revealing. Research shows that industry funding of nutrition-related scientific articles may bias conclusions in favor of sponsors’ products, with potentially significant implications for public health.3

This is now becoming widely accepted, so much so that still more research found physicians are less likely to believe and act on research findings when they are industry-sponsored.4 If that’s the case, many may have a hard time believing the featured HFCS/obesity study. There are four authors to the featured study: lead author James M. Rippe and co-authors David M. Klurfeld, John Foreyt, and Theodore J. Angelopoulos. Each one has his own ties to industry, making for a very concerning conflict of interest:

  1. Rippe: Disclosed in the journal that he and his Rippe Lifestyle Institute had received research grants and consulting fees from a variety of companies and organizations including ConAgra, Kraft Foods, PepsiCo, Weight Watchers and the Corn Refiners Association. He also disclosed in other research completed in 2012 that he has received funding from the Corn Refiners Association.5

Rippe also is an advisor to the food and beverage industry. On his health website he lists ConAgra and PepsiCo as two of several “partners.” He also disclosed in a press release on this most recent study that he is an advisor to the food and beverage industry including the Corn Refiners Association, “which funded this research with an unrestricted educational grant.”

  1. Foreyt: Disclosed in the study that he is a member of the scientific advisory panel of the Corn Refiners Association.6
  2. Klurfeld: Is a scientific and policy advisor on the American Council on Science and Health (ACSH),7 which has published material criticizing the “demonizing of high fructose corn syrup.”8
  3. Angelopoulos: Is the author of at least one other study vindicating HFCS – which was funded by PepsiCo.9 Plus he got a $200,500 research grant from Rippe Health and Lifestyle Institute for “consulting services.”10

How Sensitive are You to Fructose?

Some people may be able to process fructose more efficiently than others, and the key to assess this susceptibility to fructose-induced damage lies in evaluating your uric acid levels. The higher your uric acid, the more sensitive you are to the effects of fructose. The safest range of uric acid appears to be between 3 and 5.5 milligrams per deciliter (mg/dl), and there appears to be a steady relationship between uric acid levels and blood pressure and cardiovascular risk, even down to the range of 3 to 4 mg/dl.

Dr. Richard Johnson suggests that the ideal uric acid level is probably around 4 mg/dl for men and 3.5 mg/dl for women. I would strongly encourage everyone to have their uric acid level checked to find out how sensitive you are to fructose.

Many people who are overweight likely have uric acid levels well above 5.5. Some may even be closer to 10 or above. Measuring your uric acid levels is a very practical way to determine just how strict you need to be when it comes to your fructose consumption.

The major problem with fructose lies in the excessive amounts so many people consume. And fructose has actually been linked to over 70 health conditions in the biomedical literature, indicating that this is far bigger than just a “weight problem.”11

It’s no secret that we are eating more sugar than at any other time in history. In 1700, the average person ate four pounds of sugar a year. Today, about 25 percent of all Americans consume over 134 grams of fructose a day, according to Dr. Johnson’s research.

For most people, including if you’re overweight or obese, it would actually be wise to limit your fruit fructose to 15 grams or less, as you’re virtually guaranteed to get “hidden” fructose from just about any processed food you might eat, including condiments you might never have suspected would contain sugar.

Keep in mind that fruits also contain fructose, although an ameliorating factor is that whole fruits also contain vitamins and other antioxidants that reduce the hazardous effects of fructose. Again, one way to determine just how strict you need to be in regard to fruit consumption is to check your uric acid levels. If your levels are outside the healthy ranges listed above, then I strongly suggest you listen to your body’s biochemical feedback and reduce your fructose consumption, including that from fruit, until your uric acid levels normalize.

Bonus Weight Loss Tips You Might Not Have Heard of

For the majority of people, severely restricting non-vegetable carbohydrates such as sugars, fructose, and grains in your diet will be the key to weight loss. Refined Carbohydrates like breakfast cereals, bagels, waffles, pretzels, and most other processed foods quickly break down to sugar, increase your insulin levels, and cause insulin resistance, which is the number one underlying factor of nearly every chronic disease and condition known to man, including weight gain.

As you cut these dietary villains from your meals, you need to replace them with healthy substitutes like vegetables and healthy fats (including natural saturated fats!). You will probably need to radically increase the amount of high-nutrient, low-carbohydrate vegetables you eat, as well as make sure you are also consuming protein and healthy fats regularly.

I’ve detailed a step-by-step guide to this type of healthy eating program in my comprehensive nutrition plan, and I urge you to consult this guide if you are trying to lose weight.

Next, you’ll want to add in proper exercise. The key to boosting weight loss and getting the most out of your exercise routine is to make sure to incorporate high-intensity, short-burst-type exercises, such as my Peak Fitness Program, two to three times per week. Several studies have confirmed that exercising in shorter bursts with rest periods in between burns more fat than exercising continuously for an entire session.

Now here’s the bonus: A growing body of research suggests that intermittent fasting may in fact be a key weight loss tool. It appears particularly powerful when combined with exercise – i.e. working out while in a fasted state. Intermittent fasting is not the same thing as starving yourself; it can be as simple as skipping breakfast. You can find more details on intermittent fasting here.

Sourc: Dr. Mercola

Cardiovascular-Risk Indicators Eleva.ted in Overweight, Obese Children


Overweight and, particularly, obese school-aged children show significant increases in measures of cardiovascular risk relative to their normal-weight peers, a BMJ meta-analysis shows. Editorialists remind readers that although the results are “worrying,” it is unknown whether those risks follow the children into adulthood, independent of adult weight.

The analysis looked at 63 studies including almost 50,000 children aged 5 to 15 years from highly developed countries. Average systolic blood pressure was 4.54 mm Hg higher among overweight children and 7.49 mm Hg higher among obese children, compared with their normal-weight peers. Obese children also had increased total cholesterol, fasting glucose, fasting insulin, and insulin resistance, as well as a 19-g increase in left ventricular mass.

The editorialists liken childhood obesity to climate change, which “is at times in danger of inciting an ennui borne out of a repetition of problems without answers.”

Source: BMJ

 

 

High cardiovascular risk in severely obese young children and adolescents.


Abstract

Objective To assess the prevalence of cardiovascular risk factors in severely obese children and adolescents.

Methods A nationwide prospective surveillance study was carried out from July 2005 to July 2007 where paediatricians were asked to report all new cases of severe obesity in 2–18-year-old children to the Dutch Paediatric Surveillance Unit. Severe obesity is defined by gender and age-dependent cut-off points for body mass index based on Dutch National Growth Studies corresponding to the adult cut-off point of 35 kg/m2. Paediatricians were asked to complete a questionnaire for every severely obese child regarding socio-demographic characteristics and cardiovascular risk factors (blood pressure, fasting blood glucose and lipids).

Results In 2005, 2006 and 2007, 94%, 87% and 87%, respectively, of paediatricians in the Netherlands responded to the monthly request from the Dutch Paediatric Surveillance Unit and 500 children with newly diagnosed severe obesity were reported. 72.6% (n=363) of paediatricians responded to a subsequent questionnaire. Cardiovascular risk factor data were available in 255/307 (83%) children who were correctly classified as severely obese. 67% had at least one cardiovascular risk factor (56% hypertension, 14% high blood glucose, 0.7% type 2 diabetes and up to 54% low HDL-cholesterol). Remarkably, 62% of severely obese children aged ≤12 years already had one or more cardiovascular risk factors.

Conclusion A high number (2/3) of severely obese children have cardiovascular risk factors. Internationally accepted criteria for defining severe obesity and guidelines for early detection and treatment of severe obesity and comorbidity are urgently needed.

Source: BMJ.

 

 

Mood disorder as a specific complication of stroke

Appraising the impact of Folstein et al’s1 1977 report on ‘Mood disorder as a specific complication of stroke’ is a challenging task for someone who did not enter medical school until the mid-1980s. Stroke changed in the 1970s, and the view in retrospect appears unrecognisable. This was a dramatic change, from an intellectual backwater too dull for neurologists to even bother seeing, to become a hot topic: a disease to be studied in mega trials and a standard bearer for evidence based medicine. Prior to the 1970s, with the exception of dysphasia, neuropsychiatric complications had been given scant thought—it was a disorder that affected how people walked. It was recognised that some elderly patients became depressed after stroke but the prevailing view appeared to be “so what, they’re old and infirm, what do you expect?” It is against this backdrop that the work of researchers at John Hopkins has to be judged.

The importance of the paper was perhaps not the findings but the very fact that they published the study at all. Two years earlier their John Hopkins colleague Robert Robinson published a fascinating study demonstrating that experimentally induced strokes in rats led to alteration in cerebral metabolism of catecholamines that correlated with behavioural changes in the rats that mimicked depression.2 Folstein’s data appeared to be an early example of translational research and were widely disseminated as they appeared to link laboratory based neurobiology with clinical practice. Tantalisingly it seemed to offer a human model for studying the anatomy of depression. Appearing, as it did, contemporaneously with the development of cerebral imaging techniques, this was the impetus researchers had needed. Over the next 2 decades, 143 reports were made on this topic. Sadly, the theory of anatomical location of brain lesions as a simplistic explanation for mood disorder did not stand up to scrutiny.3 It was perhaps too good to be true; a salient reminder of the need for confirmation in humans of findings from animal models.

In critical analysis the paper itself has suffered with the passage of time. Epidemiological techniques have advanced, as has expectation of sample sizes and analysis strategies. Future investigators submitting to the journal are unlikely to get a case control study past peer review without any statistical comparisons! But for all that, it is a well written report that gets its key messages across clearly and succinctly, perhaps because the manuscript was not cluttered with t tests and hazard ratios, and that is something editors welcome in any era.

And the key messages were important—the realisation that depression after stroke was not simply an understandable reaction to disability has stood the test of time. We now know that 33% of stroke patients suffer from depression (95% CI 29% to 36%).4 We now know that this depression leads to increased disability5 and probably increased mortality.6 Most importantly, we now know that antidepressants are effective in treating it.7 Countless patients round the world are benefiting from this knowledge and that is an impact that any researcher can be proud of.

Footnotes

  • Competing interests None.
  • Provenance and peer review Commissioned; not externally peer reviewed.

References

    1. Folstein MF,
    2. Maiberger R,
    3. McHugh PR

. Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 1977;40:1018–20.

[Abstract/FREE Full text]

    1. Robinson RG,
    2. Shoemaker WJ,
    3. Schlumpf M,
    4. et al

. Effect of experimental cerebral infarction in rat brain on catecholamines and behaviour. Nature 1975;255:332–4.

[CrossRef][Medline]

    1. Carson AJ,
    2. Machale S,
    3. Allen K,
    4. et al

. Depression after stroke and lesion location: a systematic review. Lancet 2000;356:122–6.

[CrossRef][Medline][Web of Science]

    1. Hackett ML,
    2. Yapa C,
    3. Parag V,
    4. et al

. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330–40.

[Abstract/FREE Full text]

    1. Pohjasvaara T,
    2. Vataja R,
    3. Leppavuori A,
    4. et al

. Depression is an independent predictor of poor long-term functional outcome poststroke. Eur J Neurol 2001;8:315–19.

[CrossRef][Medline][Web of Science]

    1. House A,
    2. Knapp P,
    3. Bamford J,
    4. et al

. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 2001;32:696–701.

[Abstract/FREE Full text]

    1. Hackett ML,
    2. Anderson CS,
    3. House A,
    4. et al

. Interventions for treating depression after stroke. Cochrane Database Syst Rev 2008;4:CD003437.

Search Google Scholar

Source:BMJ

 

 

Could Oral FacialTherapy Be the Answer for Sleep Apnea?


Not sleeping well? You’re not alone… A recently published study1 from Sweden highlights just how common more severe sleep problems, like sleep apnea, might be. Apnea is a Greek word that means “breathe.” Sleep apnea is the inability to breathe properly, or the limitation of breath or breathing, during sleep.

The study, which included 400 women ranging in age between 20-70, found that hmycoalf of them had mild to severe sleep apnea. Among women with hypertension or who were obese, the numbers were even higher – 80 to 84 percent of them had sleep apnea. This is significant, as sleep apnea is tied to higher risks of stroke, silent brain infarction2, heart attack, and early death.

As reported by Reuters:3

“Each apnea event was defined by at a least a 10-second pause in breathing accompanied by a drop in blood oxygen levels. Women who had an average of five or more of these events during each hour of sleep were considered to have sleep apnea.

The study, which was funded by the Swedish Heart Lung Foundation, found that apnea became more common in the older age groups. Among women aged 20-44, one quarter had sleep apnea, compared to 56 percent of women aged 45-54 and 75 percent of women aged 55-70.

…Severe sleep apnea, which involves more than 30 breathing disruptions per hour, was far less common. Just 4.6 percent of women 45-54 and 14 percent of women 55-70 had severe cases. Among women of all ages with hypertension, 14 percent had severe sleep apnea, and among women who were obese, 19 percent had severe apnea.”

What is Sleep Apnea?

There are three general types of sleep apnea described in the medical literature:

  • Central apnea, which typically relates to your diaphragm and chest wall and an inability to properly pull air in
  • Obstructive apnea, which relates to an obstruction of your airway that begins in your nose and ends in your lungs
  • Mixed apnea is a combination of both

Obstructive sleep apnea consists of the frequent collapse of the airway during sleep, making it difficult for victims to breathe for periods lasting as long as 10 seconds. Those with a severe form of the disorder have at least 30 disruptions per hour. Not only do these breathing disruptions interfere with sleep, leaving you unusually tired the next day, it also reduces the amount of oxygen in your blood, which can impair the function of internal organs and/or exacerbate other health conditions you may have.

Signs and Symptoms of Sleep Apnea

Your body is constantly working to keep you alive – it’s in constant CPR mode, if you will. So at night, your body is constantly shifting and compensating to keep you breathing. One sign that you’re having trouble breathing is when your body compensates with increased forward head posture when sleeping. The worse your apnea gets, the more pronounced this forward posture becomes, because pulling your head forward helps compensate for the lack of room behind the back of your tongue.

Another common compensation that can indicate sleep apnea is frequent tossing and turning at night. This is because when you’re laying on your back, gravity will pull your jaw and tongue backward, further into your throat, which can obstruct breathing. Hence, tossing and turning may be your body’s way of keeping you breathing.

Snoring is another indication that you may have sleep apnea.

A simple test you can perform to check whether or not you’re breathing properly is to stand with your back against a wall, with your heels, buttocks, shoulder blades and head touching the wall. Say “Hello,” swallow, and then breathe. If you can speak, swallow, and breathe easily and comfortably in this position, then your mouth and throat are clear. If you cannot perform those three functions, your breathing is probably obstructed, which may be exacerbated when lying down to sleep.

Of course you could also have a professional evaluation in a sleep laboratory for a more comprehensive diagnosis. One useful new inexpensive tool for under $100 is the Zeo, which is available on Amazon. It is essentially a sleep lab that you can perform every night. It will not only tell you how long you are sleeping but when you wake up, how long you are up for, the length and times of your REM, light, and deep sleep. It then provides you with a summary sleep score that can tell you how well you slept during the night. You can then use this information to help fine tune your sleep program and monitor the effectiveness of any intervention.

You Don’t have to Be Obese to Suffer from Sleep Apnea

Years ago, sleep apnea was thought to be primarily associated with morbid obesity, which clearly can be a significant contributing factor. However, many patients diagnosed with sleep apnea today do not have a weight problem. So what’s really causing your sleep apnea?

The primary issue appears to be related to the shape and size of your mouth, and the positioning of your tongue.

The conventional treatment for sleep apnea is a machine called CPAP, which is an acronym for “continuous positive airway pressure.” The machine creates a forceful pressure that mechanically opens up your airway. But that does not address the cause of the problem, although it may provide some symptom relief.

According to Dr. Arthur Strauss, a dental physician and a diplomat of the American Board of Dental Sleep Medicine, our mouths have progressively gotten smaller through the generations due to lack of breastfeeding and poor nutrition. Breastfeeding actually helps expand the size of your child’s palate and helps move the jaw further forward – two factors that help prevent sleep apnea by creating more room for breathing. Diet is also important. Dr. Weston Price‘s pioneering work showed how diet can affect your entire mouth, not just your teeth.

If your sleep apnea is related to your tongue or jaw position, specialty trained dentists can design a custom oral appliance to address the issue. These include mandibular repositioning devices, designed to shift your jaw forward, while others help hold your tongue forward without moving your jaw. However, sleep apnea relief may also be found in the form of speech therapy treatment…

Oral Myofunctional Therapy Shown Effective for Sleep Apnea

My girlfriend, who is in no way obese, has suffered from obstructive sleep apnea for most of her adult life and it had nearly destroyed her physical health from insomnia. I recently became aware of a form of therapy called oral myofunctional therapy, which appears to have great promise for the treatment of sleep apnea. Essentially, it’s an exercise program for your mouth and tongue.

I had interviewed a dental hygienist, Carol Vander Stoep, and while in our video studio she quickly evaluated me and told me I was “tongue tied” and that it might be affecting my health. I was surprised, so I obtained an evaluation by Joy Moeller, the leading orofacial myologist in the US, and she confirmed it. So I consulted with her and started on some mouth exercises and in less than a week I noticed a remarkable improvement in my time in deep sleep as objectively measured by the Zeo. The program takes about one year to change the muscles and increase the size of the oral cavity to decrease obstructive sleep apnea, but I actually may have been suffering from this my whole life and never knew it. I will certainly keep you posted of my progress.

Although this therapy is widely known in Brazil, it is relatively unheard of in the US. As Joy explains:4

“Myofunctional therapy, also called orofacial myology, is the neuromuscular re-education or re-patterning of the oral and facial muscles. It might include muscle exercises, which create a normal freeway space dimension. Therapists are trained to eliminate negative oral habits through behavior modification techniques and promote positive growth patterns. We train people to breathe through their noses if their airways are not compromised, and if the oral breathing is an acquired habit; we teach people how to properly position their tongue at rest; we teach how to chew and swallow correctly, and we emphasize the importance of proper head and neck posture patterns.

…Therapy usually starts with establishing nasal airway (after clearance from an ENT and an Allergist) and developing a lip seal. If a patient habitually breathes through his/her mouth, the tongue rests down and the mandible drops down and back. The palate, in turn, might not develop correctly. A good myofunctional therapist will assist the patient to clear his/her nose, use correct abdominal (diaphragmatic) breathing, and then establish habitual nasal breathing.”

According to a 2007 case report published in International Archives of Otorhinolaryngology:5

“Speech therapy treatment could be considered a new therapy for snoring and obstructive sleep apnea patients because of its direct action on oral motility. The myofunctional therapy includes the correct use of the stomatognatic structures and functions by means of functional exercises (respiratory, suction, swallowing and chewing) and muscular exercises with the aim of increasing the tonus and mobility of oral and cervical structures, which can be damaged in apneic patients.”

The paper includes the case histories of two subjects, one male and one female, both of whom experienced “extreme regression of the syndrome.”

Home Testing Technologies

Myofunctional therapy strikes me as an excellent first step if you suspect you might have sleep apnea, before you start sinking money into sleep studies, expensive machines, and/or oral surgery. Furthermore, there are technologies available that can help you determine whether or not you may have a problem that may require seeing a specialist. These home technologies can also be used to evaluate how well an oral appliance is working. For example, you can:

  • Measure your snoring with iPhone apps
  • Record the sounds of you sleeping using Audacity, a free software program available online
  • Measure your blood oxygen levels with an oximeter. Oftentimes, if you have sleep apnea, you’re going to have a drop in blood oxygen. When it drops to a certain level, it indicates you have a problem

To learn more about sleep apnea, check out the American Academy of Dental Sleep Medicine’s website. Dental sleep medicine is an area of medicine that focuses on the management of sleep-related breathing disorders.

Source: Dr. Mercola